These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
513 related articles for article (PubMed ID: 22571168)
1. Bisphosphonates for osteoporosis--where do we go from here? Whitaker M; Guo J; Kehoe T; Benson G N Engl J Med; 2012 May; 366(22):2048-51. PubMed ID: 22571168 [No Abstract] [Full Text] [Related]
2. Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? Black DM; Bauer DC; Schwartz AV; Cummings SR; Rosen CJ N Engl J Med; 2012 May; 366(22):2051-3. PubMed ID: 22571169 [No Abstract] [Full Text] [Related]
3. [When should bisphosphonate treatment be discontinued?]. Eriksen EF; Halse J Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131 [No Abstract] [Full Text] [Related]
5. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate]. Miki T; Minamide T Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089 [TBL] [Abstract][Full Text] [Related]
6. Vertebral fractures and increased sensitivity to corticosteroids in a child with ulcerative colitis: successful use of pamidronate. Lucarelli S; Borrelli O; Paganelli M; Capocaccia P; Frediani T; Ferri F; Cucchiara S J Pediatr Gastroenterol Nutr; 2006 Oct; 43(4):533-5. PubMed ID: 17033531 [No Abstract] [Full Text] [Related]
7. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis]. Soen S Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264 [TBL] [Abstract][Full Text] [Related]
8. [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis]. Tanaka M; Mori H; Shimizu K; Toshiyuki ; Matsuoka ; Yamamotoya H; Minamide T; Mori M; Nozaki K; Usui T; Shimokawa K; Suzuki H; Aoyama K; Kimoto A; Sasamata M; Miyata K Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):149-57. PubMed ID: 19749488 [No Abstract] [Full Text] [Related]
9. Bisphosphonates: how do they work? Papapoulos SE Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359 [TBL] [Abstract][Full Text] [Related]
10. [Image assessment of the treatment effect on osteoporosis: bisphosphonates]. Sone T Clin Calcium; 2011 Jul; 21(7):1041-6. PubMed ID: 21719985 [TBL] [Abstract][Full Text] [Related]
11. Bone diseases. Incident fractures during treatment for osteoporosis. Vestergaard P Nat Rev Rheumatol; 2013 Sep; 9(9):508-10. PubMed ID: 23938864 [TBL] [Abstract][Full Text] [Related]
13. Use of bisphosphonates in the management of postmenopausal osteoporosis. Papapoulos SE Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579 [TBL] [Abstract][Full Text] [Related]
14. [[Antiresorptive agents in the treatment of osteoporosis]. Novak S Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401 [TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates for the prevention and treatment of osteoporosis. Maraka S; Kennel KA BMJ; 2015 Sep; 351():h3783. PubMed ID: 26333528 [TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy. J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137 [No Abstract] [Full Text] [Related]
17. Osteoporosis in men. Joy M N Engl J Med; 2008 Aug; 359(8):868; author reply 869. PubMed ID: 18724403 [No Abstract] [Full Text] [Related]
18. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them. Gasser JA Curr Opin Pharmacol; 2006 Jun; 6(3):313-8. PubMed ID: 16650802 [TBL] [Abstract][Full Text] [Related]
19. Emerging issues with bisphosphonates. Reid IR Rheum Dis Clin North Am; 2006 Nov; 32(4):691-702, vi. PubMed ID: 17288972 [TBL] [Abstract][Full Text] [Related]
20. [Vitamin K2 treatment for osteoporosis: what is the evidence today?]. Ishida Y Nihon Rinsho; 2007 Nov; 65 Suppl 9():409-14. PubMed ID: 18161141 [No Abstract] [Full Text] [Related] [Next] [New Search]